BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35389777)

  • 21. Cancer regulatory variation.
    Hennessey RC; Brown KM
    Curr Opin Genet Dev; 2021 Feb; 66():41-49. PubMed ID: 33422949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NIMBus: a negative binomial regression based Integrative Method for mutation Burden Analysis.
    Zhang J; Liu J; McGillivray P; Yi C; Lochovsky L; Lee D; Gerstein M
    BMC Bioinformatics; 2020 Oct; 21(1):474. PubMed ID: 33092526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent somatic mutations in regulatory regions of human cancer genomes.
    Melton C; Reuter JA; Spacek DV; Snyder M
    Nat Genet; 2015 Jul; 47(7):710-6. PubMed ID: 26053494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional and genetic determinants of mutation rate variability in regulatory elements of cancer genomes.
    Lee CA; Abd-Rabbo D; Reimand J
    Genome Biol; 2021 May; 22(1):133. PubMed ID: 33941236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.
    Rheinbay E; Nielsen MM; Abascal F; Wala JA; Shapira O; Tiao G; Hornshøj H; Hess JM; Juul RI; Lin Z; Feuerbach L; Sabarinathan R; Madsen T; Kim J; Mularoni L; Shuai S; Lanzós A; Herrmann C; Maruvka YE; Shen C; Amin SB; Bandopadhayay P; Bertl J; Boroevich KA; Busanovich J; Carlevaro-Fita J; Chakravarty D; Chan CWY; Craft D; Dhingra P; Diamanti K; Fonseca NA; Gonzalez-Perez A; Guo Q; Hamilton MP; Haradhvala NJ; Hong C; Isaev K; Johnson TA; Juul M; Kahles A; Kahraman A; Kim Y; Komorowski J; Kumar K; Kumar S; Lee D; Lehmann KV; Li Y; Liu EM; Lochovsky L; Park K; Pich O; Roberts ND; Saksena G; Schumacher SE; Sidiropoulos N; Sieverling L; Sinnott-Armstrong N; Stewart C; Tamborero D; Tubio JMC; Umer HM; Uusküla-Reimand L; Wadelius C; Wadi L; Yao X; Zhang CZ; Zhang J; Haber JE; Hobolth A; Imielinski M; Kellis M; Lawrence MS; von Mering C; Nakagawa H; Raphael BJ; Rubin MA; Sander C; Stein LD; Stuart JM; Tsunoda T; Wheeler DA; Johnson R; Reimand J; Gerstein M; Khurana E; Campbell PJ; López-Bigas N; ; ; Weischenfeldt J; Beroukhim R; Martincorena I; Pedersen JS; Getz G;
    Nature; 2020 Feb; 578(7793):102-111. PubMed ID: 32025015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Candidate Cancer Driver Mutations in Distal Regulatory Elements and Long-Range Chromatin Interaction Networks.
    Zhu H; Uusküla-Reimand L; Isaev K; Wadi L; Alizada A; Shuai S; Huang V; Aduluso-Nwaobasi D; Paczkowska M; Abd-Rabbo D; Ocsenas O; Liang M; Thompson JD; Li Y; Ruan L; Krassowski M; Dzneladze I; Simpson JT; Lupien M; Stein LD; Boutros PC; Wilson MD; Reimand J
    Mol Cell; 2020 Mar; 77(6):1307-1321.e10. PubMed ID: 31954095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Core promoter mutation contributes to abnormal gene expression in bladder cancer.
    Huang T; Li J; Wang SM
    BMC Cancer; 2022 Jan; 22(1):68. PubMed ID: 35033028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations.
    Lochovsky L; Zhang J; Fu Y; Khurana E; Gerstein M
    Nucleic Acids Res; 2015 Sep; 43(17):8123-34. PubMed ID: 26304545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide mapping of somatic mutation rates uncovers drivers of cancer.
    Sherman MA; Yaari AU; Priebe O; Dietlein F; Loh PR; Berger B
    Nat Biotechnol; 2022 Nov; 40(11):1634-1643. PubMed ID: 35726091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of Cancer Driver Long Noncoding RNAs across 1112 Tumour Genomes: New Candidates and Distinguishing Features.
    Lanzós A; Carlevaro-Fita J; Mularoni L; Reverter F; Palumbo E; Guigó R; Johnson R
    Sci Rep; 2017 Jan; 7():41544. PubMed ID: 28128360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A non-coding cancer mutation disrupting an HNF4α binding motif affects an enhancer regulating genes associated to the progression of liver cancer.
    Cavalli M; Diamanti K; Pan G; Dabrowski MJ; Komorowski J; Wadelius C
    Exp Oncol; 2021 Mar; 43(1):2-6. PubMed ID: 33785712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations.
    Zhou S; Treloar AE; Lupien M
    Cancer Discov; 2016 Nov; 6(11):1215-1229. PubMed ID: 27807102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer.
    Lowdon RF; Wang T
    PLoS One; 2017; 12(3):e0174032. PubMed ID: 28333948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Highly recurrent TERT promoter mutations in human melanoma.
    Huang FW; Hodis E; Xu MJ; Kryukov GV; Chin L; Garraway LA
    Science; 2013 Feb; 339(6122):957-9. PubMed ID: 23348506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profile of Basal Cell Carcinoma Mutations and Copy Number Alterations - Focus on Gene-Associated Noncoding Variants.
    Nawrocka PM; Galka-Marciniak P; Urbanek-Trzeciak MO; M-Thirusenthilarasan I; Szostak N; Philips A; Susok L; Sand M; Kozlowski P
    Front Oncol; 2021; 11():752579. PubMed ID: 34900699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional analysis of recurrent CDC20 promoter variants in human melanoma.
    Godoy PM; Oyedeji A; Mudd JL; Morikis VA; Zarov AP; Longmore GD; Fields RC; Kaufman CK
    Commun Biol; 2023 Nov; 6(1):1216. PubMed ID: 38030698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Intolerance of Regulatory Sequence to Genetic Variation Predicts Gene Dosage Sensitivity.
    Petrovski S; Gussow AB; Wang Q; Halvorsen M; Han Y; Weir WH; Allen AS; Goldstein DB
    PLoS Genet; 2015 Sep; 11(9):e1005492. PubMed ID: 26332131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occurrence, functionality and abundance of the TERT promoter mutations.
    Rachakonda S; Hoheisel JD; Kumar R
    Int J Cancer; 2021 Dec; 149(11):1852-1862. PubMed ID: 34313327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of Regulatory DNA Sequences by Dual-Luciferase Reporter Assays in Ewing Sarcoma.
    Hölting TLB; Knott MML
    Methods Mol Biol; 2021; 2226():139-149. PubMed ID: 33326098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.